Loading
A phase 3 trial of FES PET in Breast cancer, run by Asan Medical Center, completed.
Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer is a phase 3 interventional study registered as NCT01986569 by Asan Medical Center, with 93 participants recorded, started 2013-11 and reaching its primary completion in 2016-11. Interventions recorded: [18F]fluoroestradiol (FES). Conditions recorded: Recurrent Breast Cancer, Stage IV Breast Cancer.
Linked to the technology FES PET because the registry's title names it ("18f fluoroestradiol pet") and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Shares FES, FES PET (oestrogen receptor imaging), Breast cancer (all types) and the tag pipeline.
Shares FES, FES PET (oestrogen receptor imaging), Breast cancer (all types) and the tag pipeline.
Shares FES, Breast cancer (all types) and the tag pipeline.
Shares FES, Breast cancer (all types) and the tag pipeline.
Shares FES, Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.